Carboplatin pharmacokinetics in young children with brain tumors

Margaret E. Tonda, Richard L. Heideman, William P. Petros, Henry S. Friedman, Daryl J. Murry, John H. Rodman

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Purpose: The pharmacokinetic parameters and maximal tolerated systemic exposure were determined for carboplatin in young children given in combination with cyclophosphamide and etoposide. Patients and methods: Carboplatin was administered as part of a multiagent chemotherapy regimen to 21 pediatric patients less than 5 years of age with newly diagnosed, malignant central nervous system tumors. Patients received cyclophosphamide, 1.2 g/m2, on day 1 and carboplatin on day 2 followed by etoposide, 100 mg/m2, each day. Carboplatin doses were calculated to achieve a targeted area under the serum concentration versus time curve (TAUC) of 5, 6.5 or 8 mg/ml.min based on each patient's measured glomerular filtration rate (GFR). Carboplatin pharmacokinetic parameters were determined after course 1 and then after every third course of therapy. Results: The median carboplatin clearance and GFR after course 1 were 118 and 98 ml/min per m2, respectively. Targeted doses based on measured GFR reliably achieved the TAUC for carboplatin. The median (range) carboplatin clearance for four children less than 1 year of age was 76 (66-84) ml/min per m2, significantly lower (P = 0.05) than the value of 131 (80-158) ml/min per m2 for children from 1 to 4 years of age. The mean carboplatin clearance declined by 23% in 12 patients studied from course 1 to course 4 of therapy. The decrease was greater than 20% (range 20-53%) in 7 of the 12 patients studied. Conclusion: Carboplatin clearance for children aged between 1 and 4 years at diagnosis is approximately 45% higher than previously reported for pediatric patients, but declines after four courses of therapy. For children less than 1 year of age, carboplatin clearance per square meter is approximately 40% lower than patients 1 to 4 years of age. There are corresponding differences in GFR that provide a plausible explanation for the age and therapy-related changes in carboplatin clearance. Toxicity was acceptable for patients treated at a TAUC of 6.5 mg/ml.min for carboplatin given with etoposide and cyclophosphamide. The average carboplatin dose required for this AUC was 767 mg/m2.

Original languageEnglish (US)
Pages (from-to)395-400
Number of pages6
JournalCancer Chemotherapy and Pharmacology
Volume38
Issue number5
DOIs
StatePublished - Sep 5 1996

Fingerprint

Pharmacokinetics
Carboplatin
Brain Neoplasms
Tumors
Brain
Glomerular Filtration Rate
Etoposide
Cyclophosphamide
Pediatrics
Central Nervous System Neoplasms
Chemotherapy
Neurology
Therapeutics
Area Under Curve
Toxicity

Keywords

  • Brain tumors
  • Carboplatin
  • Glomerular filtration rate
  • Pediatrics
  • Pharmacokinetics

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Tonda, M. E., Heideman, R. L., Petros, W. P., Friedman, H. S., Murry, D. J., & Rodman, J. H. (1996). Carboplatin pharmacokinetics in young children with brain tumors. Cancer Chemotherapy and Pharmacology, 38(5), 395-400. https://doi.org/10.1007/s002800050502

Carboplatin pharmacokinetics in young children with brain tumors. / Tonda, Margaret E.; Heideman, Richard L.; Petros, William P.; Friedman, Henry S.; Murry, Daryl J.; Rodman, John H.

In: Cancer Chemotherapy and Pharmacology, Vol. 38, No. 5, 05.09.1996, p. 395-400.

Research output: Contribution to journalArticle

Tonda, ME, Heideman, RL, Petros, WP, Friedman, HS, Murry, DJ & Rodman, JH 1996, 'Carboplatin pharmacokinetics in young children with brain tumors', Cancer Chemotherapy and Pharmacology, vol. 38, no. 5, pp. 395-400. https://doi.org/10.1007/s002800050502
Tonda, Margaret E. ; Heideman, Richard L. ; Petros, William P. ; Friedman, Henry S. ; Murry, Daryl J. ; Rodman, John H. / Carboplatin pharmacokinetics in young children with brain tumors. In: Cancer Chemotherapy and Pharmacology. 1996 ; Vol. 38, No. 5. pp. 395-400.
@article{3b27bf683cd74593876e2037eb10467f,
title = "Carboplatin pharmacokinetics in young children with brain tumors",
abstract = "Purpose: The pharmacokinetic parameters and maximal tolerated systemic exposure were determined for carboplatin in young children given in combination with cyclophosphamide and etoposide. Patients and methods: Carboplatin was administered as part of a multiagent chemotherapy regimen to 21 pediatric patients less than 5 years of age with newly diagnosed, malignant central nervous system tumors. Patients received cyclophosphamide, 1.2 g/m2, on day 1 and carboplatin on day 2 followed by etoposide, 100 mg/m2, each day. Carboplatin doses were calculated to achieve a targeted area under the serum concentration versus time curve (TAUC) of 5, 6.5 or 8 mg/ml.min based on each patient's measured glomerular filtration rate (GFR). Carboplatin pharmacokinetic parameters were determined after course 1 and then after every third course of therapy. Results: The median carboplatin clearance and GFR after course 1 were 118 and 98 ml/min per m2, respectively. Targeted doses based on measured GFR reliably achieved the TAUC for carboplatin. The median (range) carboplatin clearance for four children less than 1 year of age was 76 (66-84) ml/min per m2, significantly lower (P = 0.05) than the value of 131 (80-158) ml/min per m2 for children from 1 to 4 years of age. The mean carboplatin clearance declined by 23{\%} in 12 patients studied from course 1 to course 4 of therapy. The decrease was greater than 20{\%} (range 20-53{\%}) in 7 of the 12 patients studied. Conclusion: Carboplatin clearance for children aged between 1 and 4 years at diagnosis is approximately 45{\%} higher than previously reported for pediatric patients, but declines after four courses of therapy. For children less than 1 year of age, carboplatin clearance per square meter is approximately 40{\%} lower than patients 1 to 4 years of age. There are corresponding differences in GFR that provide a plausible explanation for the age and therapy-related changes in carboplatin clearance. Toxicity was acceptable for patients treated at a TAUC of 6.5 mg/ml.min for carboplatin given with etoposide and cyclophosphamide. The average carboplatin dose required for this AUC was 767 mg/m2.",
keywords = "Brain tumors, Carboplatin, Glomerular filtration rate, Pediatrics, Pharmacokinetics",
author = "Tonda, {Margaret E.} and Heideman, {Richard L.} and Petros, {William P.} and Friedman, {Henry S.} and Murry, {Daryl J.} and Rodman, {John H.}",
year = "1996",
month = "9",
day = "5",
doi = "10.1007/s002800050502",
language = "English (US)",
volume = "38",
pages = "395--400",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Carboplatin pharmacokinetics in young children with brain tumors

AU - Tonda, Margaret E.

AU - Heideman, Richard L.

AU - Petros, William P.

AU - Friedman, Henry S.

AU - Murry, Daryl J.

AU - Rodman, John H.

PY - 1996/9/5

Y1 - 1996/9/5

N2 - Purpose: The pharmacokinetic parameters and maximal tolerated systemic exposure were determined for carboplatin in young children given in combination with cyclophosphamide and etoposide. Patients and methods: Carboplatin was administered as part of a multiagent chemotherapy regimen to 21 pediatric patients less than 5 years of age with newly diagnosed, malignant central nervous system tumors. Patients received cyclophosphamide, 1.2 g/m2, on day 1 and carboplatin on day 2 followed by etoposide, 100 mg/m2, each day. Carboplatin doses were calculated to achieve a targeted area under the serum concentration versus time curve (TAUC) of 5, 6.5 or 8 mg/ml.min based on each patient's measured glomerular filtration rate (GFR). Carboplatin pharmacokinetic parameters were determined after course 1 and then after every third course of therapy. Results: The median carboplatin clearance and GFR after course 1 were 118 and 98 ml/min per m2, respectively. Targeted doses based on measured GFR reliably achieved the TAUC for carboplatin. The median (range) carboplatin clearance for four children less than 1 year of age was 76 (66-84) ml/min per m2, significantly lower (P = 0.05) than the value of 131 (80-158) ml/min per m2 for children from 1 to 4 years of age. The mean carboplatin clearance declined by 23% in 12 patients studied from course 1 to course 4 of therapy. The decrease was greater than 20% (range 20-53%) in 7 of the 12 patients studied. Conclusion: Carboplatin clearance for children aged between 1 and 4 years at diagnosis is approximately 45% higher than previously reported for pediatric patients, but declines after four courses of therapy. For children less than 1 year of age, carboplatin clearance per square meter is approximately 40% lower than patients 1 to 4 years of age. There are corresponding differences in GFR that provide a plausible explanation for the age and therapy-related changes in carboplatin clearance. Toxicity was acceptable for patients treated at a TAUC of 6.5 mg/ml.min for carboplatin given with etoposide and cyclophosphamide. The average carboplatin dose required for this AUC was 767 mg/m2.

AB - Purpose: The pharmacokinetic parameters and maximal tolerated systemic exposure were determined for carboplatin in young children given in combination with cyclophosphamide and etoposide. Patients and methods: Carboplatin was administered as part of a multiagent chemotherapy regimen to 21 pediatric patients less than 5 years of age with newly diagnosed, malignant central nervous system tumors. Patients received cyclophosphamide, 1.2 g/m2, on day 1 and carboplatin on day 2 followed by etoposide, 100 mg/m2, each day. Carboplatin doses were calculated to achieve a targeted area under the serum concentration versus time curve (TAUC) of 5, 6.5 or 8 mg/ml.min based on each patient's measured glomerular filtration rate (GFR). Carboplatin pharmacokinetic parameters were determined after course 1 and then after every third course of therapy. Results: The median carboplatin clearance and GFR after course 1 were 118 and 98 ml/min per m2, respectively. Targeted doses based on measured GFR reliably achieved the TAUC for carboplatin. The median (range) carboplatin clearance for four children less than 1 year of age was 76 (66-84) ml/min per m2, significantly lower (P = 0.05) than the value of 131 (80-158) ml/min per m2 for children from 1 to 4 years of age. The mean carboplatin clearance declined by 23% in 12 patients studied from course 1 to course 4 of therapy. The decrease was greater than 20% (range 20-53%) in 7 of the 12 patients studied. Conclusion: Carboplatin clearance for children aged between 1 and 4 years at diagnosis is approximately 45% higher than previously reported for pediatric patients, but declines after four courses of therapy. For children less than 1 year of age, carboplatin clearance per square meter is approximately 40% lower than patients 1 to 4 years of age. There are corresponding differences in GFR that provide a plausible explanation for the age and therapy-related changes in carboplatin clearance. Toxicity was acceptable for patients treated at a TAUC of 6.5 mg/ml.min for carboplatin given with etoposide and cyclophosphamide. The average carboplatin dose required for this AUC was 767 mg/m2.

KW - Brain tumors

KW - Carboplatin

KW - Glomerular filtration rate

KW - Pediatrics

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=0029763403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029763403&partnerID=8YFLogxK

U2 - 10.1007/s002800050502

DO - 10.1007/s002800050502

M3 - Article

C2 - 8765431

AN - SCOPUS:0029763403

VL - 38

SP - 395

EP - 400

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 5

ER -